Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a seizure drug soothe IBS belly pain?

NCT ID NCT02973542

Symptom relief Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether ethosuximide, a drug used for epilepsy, can reduce belly pain in people with irritable bowel syndrome (IBS). 162 adults with IBS took either the drug or a placebo. The goal was to see if the drug could lower pain and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ethosuximide
What this could lead to
If it works, this could point toward a new treatment option for abdominal pain in irritable bowel syndrome.
What could go wrong
This is a phase 2 trial, so results are still early. The drug may not prove effective or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

162 people

The number who actually took part.

Started

Feb 2018

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, * Man, * Women, Negative pregnancy test and effective contraception, * IBS defined by the Rome criteria IV * During the previous seven days the inclusion visit, average NRS pain ≥ 4, * IBS Treatment stable for 1 month * Patients affiliated to the French Social Security, * Patients with the informed consent were obtained. Exclusion Criteria: * Breastfeeding * Diabetic patients * Known renal or hepatic impairment, * Significant liver function abnormalities (transaminases\> 3N, cholestasis) and renal (MDRD \<60 ml / min) * Addiction to alcohol and / or drugs, * AEDs taken (epilepsy or chronic pain) * chronic pain of greater intensity than that related to IBS, * Allergy succinimides (ethosuximide, methsuximide, phensuximide) * History or current severe depression (hospitalization, long-term antidepressant treatment) * Psychotic disorders, * Patients exclusion period, or total exceeded authorized allowances * Patients undergoing a measure of legal protection (trusteeship, guardianship ...).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Irritable bowel syndrome

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.